CN1142940C - 含有mpl配体的药物组合物 - Google Patents

含有mpl配体的药物组合物 Download PDF

Info

Publication number
CN1142940C
CN1142940C CNB971802777A CN97180277A CN1142940C CN 1142940 C CN1142940 C CN 1142940C CN B971802777 A CNB971802777 A CN B971802777A CN 97180277 A CN97180277 A CN 97180277A CN 1142940 C CN1142940 C CN 1142940C
Authority
CN
China
Prior art keywords
composition
amino acid
leu
sorbitol powder
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB971802777A
Other languages
English (en)
Chinese (zh)
Other versions
CN1239480A (zh
Inventor
D・N・布雷姆斯
D·N·布雷姆斯
特雷乌黑特
M·J·特雷乌黑特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN1239480A publication Critical patent/CN1239480A/zh
Application granted granted Critical
Publication of CN1142940C publication Critical patent/CN1142940C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
CNB971802777A 1996-10-04 1997-09-12 含有mpl配体的药物组合物 Expired - Fee Related CN1142940C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72612396A 1996-10-04 1996-10-04
US08/726,123 1996-10-04

Publications (2)

Publication Number Publication Date
CN1239480A CN1239480A (zh) 1999-12-22
CN1142940C true CN1142940C (zh) 2004-03-24

Family

ID=24917340

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB971802777A Expired - Fee Related CN1142940C (zh) 1996-10-04 1997-09-12 含有mpl配体的药物组合物

Country Status (7)

Country Link
JP (1) JP2001501619A (ja)
KR (1) KR100408229B1 (ja)
CN (1) CN1142940C (ja)
AU (1) AU4344697A (ja)
HK (1) HK1024490A1 (ja)
TW (1) TW561050B (ja)
WO (1) WO1998014476A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8357513B1 (en) 1994-01-03 2013-01-22 Genentech, Inc. Nucleic acids encoding mpl ligand (thrombopoietin) and fragments thereof
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
HUP0203133A3 (en) * 1999-10-04 2005-07-28 Chiron Corp Emeryville Stabilized liquid polypeptide-containing pharmaceutical compositions
US6495534B2 (en) 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
AU2001280161A1 (en) * 2000-08-24 2002-03-04 Kirin Beer Kabushiki Kaisha C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes
US7172905B2 (en) 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
EP1573006B1 (en) * 2002-12-13 2009-11-11 ZymoGenetics, Inc. Il-21 production in prokaryotic hosts
DE602004029039D1 (de) 2003-07-07 2010-10-21 Hills Pet Nutrition Inc Zusammensetzungen für einen verbesserten oxidationsstatus bei katzen
AU2011265555B2 (en) * 2006-04-21 2016-03-10 Amgen Inc. Lyophilized therapeutic peptibody formulations
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
JP5577098B2 (ja) * 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
AU2014201388C1 (en) * 2006-12-21 2017-02-02 Amgen Inc. Stable Buffered Formulations Containing Polypeptides
CN102552184A (zh) * 2012-02-16 2012-07-11 山东泉港药业有限公司 一种血小板生成素拟肽冻干制剂
KR20150056846A (ko) 2012-09-20 2015-05-27 모르포시스 아게 류마티스 관절염에 대한 치료
US10273268B2 (en) * 2016-06-16 2019-04-30 Janssen Vaccines & Prevention B.V. HIV vaccine formulation
MX2020004936A (es) * 2017-11-16 2020-08-27 Amgen Inc Composiciones estables de compuestos de carfilzomib pegilado.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
RO115788B1 (ro) * 1994-03-31 2000-06-30 Amgen Inc. Polipeptidă mgdf, derivat de polipeptidă mgdf, polipeptidă mgdf mono-pegilată şi procedee de obţinere a acestora
NZ303588A (en) * 1995-02-15 1999-02-25 Amgen Inc Mpl ligand analogs having one or more changed glycosylation sites uses for these ligand analogs and dna sequences encoding them
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
TW497972B (en) * 1995-06-08 2002-08-11 Kirin Brewery Stable thrombopoietin (TPO)-containing lyophilized compositions
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only

Also Published As

Publication number Publication date
WO1998014476A1 (en) 1998-04-09
TW561050B (en) 2003-11-11
KR20000048905A (ko) 2000-07-25
KR100408229B1 (ko) 2003-12-01
AU4344697A (en) 1998-04-24
JP2001501619A (ja) 2001-02-06
CN1239480A (zh) 1999-12-22
HK1024490A1 (en) 2000-10-13

Similar Documents

Publication Publication Date Title
CN1142940C (zh) 含有mpl配体的药物组合物
CN1071760C (zh) N－端化学修饰的蛋白质组合物及方法
CN1241548C (zh) 稳定的蛋白质∶磷脂组合物和方法
CN1184233C (zh) 促红血球生成素偶联物
CN1103782C (zh) 单聚乙二醇化的mgdf多肽
CN1245216C (zh) 稳定化的含多肽的液体药物组合物
CN1236370A (zh) 化学修饰的多肽
CN1333785A (zh) 干扰素－β融合蛋白及用途
CN1309705A (zh) Il－2选择性激动剂和拮抗剂
CN1165539A (zh) 肽及蛋白质的修饰
CN1159830A (zh) 免疫调节剂
CN1227604A (zh) 多种变异的il－3造血生成融合蛋白
CN1220670A (zh) 干细胞增殖抑制剂和刺激剂及其用途
CN1173183A (zh) 含有水溶性聚合物的bdnf与nt－3的结合物
CN1150458A (zh) 用于刺激造血的通式为gm-csf-l-epo或epo-l-gm-csf的杂合分子
CN101080420A (zh) 胸腺特异性蛋白质
CN1861634A (zh) 犬干扰素α、制备方法和用途
CN1284134A (zh) 利用毕赤氏酵母表达系统生产抗生血管蛋白质∶制管张素,内抑制素或静息蛋白的方法
EP0426521A1 (fr) L'utilisation de l'interleukine 2 pour le traitement des leucémies
CN1142186A (zh) 用白介素-10激活外周血单核细胞的细胞溶解活性
CN1533808A (zh) 治疗冠状病毒感染和sars的组合物与方法
CN1735428A (zh) 伴侣蛋白10的免疫抑制作用
CN1143325A (zh) 使哺乳动物的恶性细胞选择性地处于甲硫氯酸饥饿状态的方法
CN1227027C (zh) 新组合物
CN1684978A (zh) 糖基化的人粒细胞集落刺激因子(g－csf)同种型

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1024490

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040324

Termination date: 20100912